Head to Head Survey: Osiris Therapeutics (OSIR) vs. Anavex Life Sciences (AVXL)

Osiris Therapeutics (OTCMKTS: OSIR) and Anavex Life Sciences (NASDAQ:AVXL) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.

Volatility & Risk

Osiris Therapeutics has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500. Comparatively, Anavex Life Sciences has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Osiris Therapeutics and Anavex Life Sciences, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Osiris Therapeutics 0 0 0 0 N/A
Anavex Life Sciences 0 0 2 0 3.00

Anavex Life Sciences has a consensus price target of $14.50, indicating a potential upside of 360.32%. Given Anavex Life Sciences’ higher possible upside, analysts plainly believe Anavex Life Sciences is more favorable than Osiris Therapeutics.

Earnings & Valuation

This table compares Osiris Therapeutics and Anavex Life Sciences’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Osiris Therapeutics $59.87 million 3.35 -$1.78 million N/A N/A
Anavex Life Sciences N/A N/A -$14.73 million ($0.33) -9.55

Osiris Therapeutics has higher revenue and earnings than Anavex Life Sciences.

Institutional & Insider Ownership

0.3% of Osiris Therapeutics shares are held by institutional investors. Comparatively, 23.9% of Anavex Life Sciences shares are held by institutional investors. 44.6% of Osiris Therapeutics shares are held by company insiders. Comparatively, 11.6% of Anavex Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Osiris Therapeutics and Anavex Life Sciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Osiris Therapeutics N/A N/A N/A
Anavex Life Sciences N/A -70.10% -63.39%

Summary

Osiris Therapeutics beats Anavex Life Sciences on 5 of the 9 factors compared between the two stocks.

About Osiris Therapeutics

Osiris Therapeutics, Inc. is a cellular and regenerative medicine company. The Company is focused on researching, developing and marketing products in the wound, orthopedic, and sports medicine markets. The Company operates through Biosurgery business segment, which focuses on products for wound care, orthopedics, and sports medicine to harness the ability of cells and novel constructs to promote the body’s natural healing. The Company’s products include Grafix, Stravix, TruSkin, Cartiform and BIO4. The Company produces and distributes Grafix for acute and chronic wounds; Stravix for tendon repair; TruSkin for wound closure; Cartiform, a viable cartilage mesh for cartilage repair, and BIO4 for bone growth. The Company’s BioSmart cryopreservation process retains the native characteristics and inherent functionality of tissue. Its BioSmart process includes preservation of the three dimensional (3D) matrix, endogenous growth factors, and tissue-resident cells.

About Anavex Life Sciences

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases. The Company’s SIGMACEPTOR Discovery Platform produced small molecule drug candidates with unique modes of action. Sigma receptors may be targets for therapeutics to combat many human diseases, including Alzheimer’s disease. When bound by the appropriate ligands, sigma receptors influence the functioning of multiple biochemical signals that are involved in the pathogenesis (origin or development) of disease.

What are top analysts saying about Osiris Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Osiris Therapeutics and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit